Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 21, 2025Frontiers in NeurologyOpen Access

Overall, 58.4% of pwRMS with continuous treatment achieved CONFIDENCE treatment success from baseline until year 5 (74.0% and 50.3% of pwRMS with 0 and ≥3 previous MS therapies, respectively).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Early high-efficacy treatment for people with relapsing multiple sclerosis may provide better long-term outcomes compared with the escalation strategy.

Does ocrelizumab maintain long-term treatment success and safety in people with relapsing multiple sclerosis?

Population

2,261 pwRMS treated with ≥1 dose of ocrelizumab in Germany

Comparison

Ocrelizumab treatment stratified by number of previous MS therapies

Design

Non-interventional post-authorization safety study

Follow-up

Up to 5.5 years

Authors

MBMathias ButtmannMWMartin S. WeberSMSven G. Meuth

Discussion

Loading...

Member takes

Overview

May support earlier ocrelizumab consideration in RMS; leaves open RCTs of sequencing versus escalation.

Structured PICO

Does ocrelizumab maintain long-term treatment success and safety in people with relapsing multiple sclerosis?

P
Population
2,261 people with relapsing multiple sclerosis (pwRMS) treated with ≥1 dose of ocrelizumab, mean age 41.16 years, in a German real-world cohort.
I
Intervention
Ocrelizumab for up to 5.5 years
O
Outcome
CONFIDENCE treatment success (proportion of people with no clinical disease activity measured by relapse or disease progression and no treatment discontinuation due to adverse event or lack of therapeutic effectiveness)composite

Ocrelizumab treatment in a real-world German cohort maintained high rates of treatment success over 5 years, supporting early high-efficacy intervention in relapsing multiple sclerosis.

Cite This Study

Buttmann et al. (2025) studied this question.

synapsesocial.com/papers/6a7fbee9138fa0ec199fed58https://doi.org/10.3389/fneur.2025.1564327
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study2026 · 1 citations
  2. 2Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension2023 · 31 citations
  3. 3Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity2026
  4. 4A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 Year2026
  5. 5Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis2024 · 4 citations